Edison Investment Research - Pharmaceutical & healthcare - International Stem Cell : International Stem Cell (ISCO) is an early-stage cell therapy company currently in clinical trials to treat Parkinson’s disease (PD). In November, the company presented interim six-month results from the first cohort of four patients in its Phase I trial of ISC-hpNSC in PD. Positive signals were seen in a variety of measures, which include daily living, mobility, depression and compulsive disorders.
ISIN: US4603782016
Original Article: International Stem Cell (ISCO) - Moving forward in Parkinsons and TBI